Cancer is a complicated family of diseases that causes major hurdles for global health. Several studies on cancer biology and cancer treatment strategies have revealed that cancer is highly genetically diverse and heterogenic in nature. The complexity of cancer is due to the highly inflammatory microenvironment which resembles wound healing process and highly acidic in nature. Hence, this condition is referred as cancer related inflammation (CRI) that drives the cancer resistance and subsequent recurrence of cancer after treatment. The major deregulated pathways associated with CRI are nuclear factor kappa B (NF-κB) and phosphoinositol-3-kinases (PI3-K) involved in cancer growth, proliferation, cancer cell survival and metastasis. Therefore, the protein factors of these pathways seem to be an attractive target for the molecular targetted therapy for cancer. However, efficient cancer treatment relies on the stages of cancer and the response to the treatment. Hence, cancer specific inflammatory components are the major targets for drug discovery, development and associated clinical trials.